Herpes Zoster Market Outlook:
Herpes Zoster Market size was valued at USD 236.44 million in 2025 and is set to exceed USD 333.52 million by 2035, expanding at over 3.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of herpes zoster is estimated at USD 243.89 million.
Expenditure on improved healthcare including diagnosis, treatment, and therapeutics is one of the major growth factors in the herpes zoster market. An NLM report, published in January 2022, published an estimation of the associated expenses in the U.S. related to herpes simplex virus diagnosis and management. It revealed that the screening, episodic therapy, suppressive therapy, and hospitalization for neonatal care ranged from USD 7–100, USD 0.53–35, USD 240–2580/year, and USD 5321–32,683. Such countries with well-developed medical facilities play a pivotal role in offering wider access to treatment and prevention. Thus, the significant contribution in reducing the prevalence and fatalities has propelled the production and development of these solutions.
The governments in such countries are also attributing to the expansion of the herpes zoster market by promoting the importance of treating and preventing shingles. In addition, their efforts to improve healthcare delivery and drug discoveries are inspiring research institutions to introduce new options for patients, broadening the product range in this sector. For instance, in August 2023, a team of R&D at the University of Georgia developed and patented a new molecule, POM-L-BHDU to offer an effective treatment for shingles. The POM-L-BHDU, 0.2% formulated in cocoa butter showed promising results against herpes simplex 1 and the varicella-zoster viruses in topical studies on adult human skin. The team aims to put the molecule on clinical trials to commercialize it as a broad-spectrum solution.
